Parkman Healthcare Partners LLC Raises Holdings in DexCom, Inc. (NASDAQ:DXCM)

Parkman Healthcare Partners LLC grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 11.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,550 shares of the medical device company's stock after acquiring an additional 7,962 shares during the period. Parkman Healthcare Partners LLC's holdings in DexCom were worth $6,109,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Czech National Bank boosted its holdings in shares of DexCom by 3.7% in the 4th quarter. Czech National Bank now owns 84,689 shares of the medical device company's stock valued at $6,586,000 after buying an additional 3,057 shares during the period. Capital Investment Advisors LLC bought a new stake in DexCom in the 4th quarter valued at about $206,000. Cullen Investment Group LTD. lifted its position in DexCom by 5.6% in the 4th quarter. Cullen Investment Group LTD. now owns 11,502 shares of the medical device company's stock valued at $895,000 after purchasing an additional 614 shares during the last quarter. 180 Wealth Advisors LLC bought a new stake in DexCom in the 4th quarter valued at about $255,000. Finally, Cardinal Point Capital Management ULC bought a new stake in DexCom in the 4th quarter valued at about $249,000. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Trading Up 1.5%

DexCom stock traded up $1.26 during mid-day trading on Monday, reaching $86.74. 875,471 shares of the company traded hands, compared to its average volume of 4,191,662. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm's 50 day moving average price is $72.01 and its 200 day moving average price is $77.69. The firm has a market capitalization of $34.01 billion, a price-to-earnings ratio of 60.65, a P/E/G ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $132.09.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period last year, the company posted $0.32 earnings per share. On average, analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on DXCM. Cfra Research upgraded shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Citigroup increased their target price on DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Morgan Stanley lifted their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Mizuho started coverage on shares of DexCom in a research report on Thursday, April 10th. They set an "outperform" rating and a $85.00 target price for the company. Finally, Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, DexCom presently has an average rating of "Moderate Buy" and a consensus target price of $98.11.

Insider Buying and Selling

In related news, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the sale, the chief operating officer now owns 313,497 shares of the company's stock, valued at $22,063,918.86. The trade was a 4.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares of the company's stock, valued at $26,183,401.02. The trade was a 8.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 66,926 shares of company stock worth $4,734,384 over the last three months. 0.32% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.